德谷胰岛素联合达格列净对老年2型糖尿病患者的疗效及安全性评估  

Efficacy and safety evaluation of insulin degludec combined with dapagliflozin in elderly patients with type 2 diabetes mellitus

作　　者：张晓青 苗翠晓 陈凯庭 董学勤 朱卉 何静 ZHANG Xiaoqing;MIAO Cuixiao;CHEN Kaiting(Department of Endocrinology,Shijiazhuang People’s Hospital,Hebei,Shijiazhuang 050000,China)

机构地区：[1]河北省石家庄市人民医院内分泌三科,050000 [2]河北省石家庄市人民医院普外三科,050000

出　　处：《河北医药》2023年第14期2161-2164,共4页Hebei Medical Journal

基　　金：石家庄市科学技术研究与发展计划(编号:191200923)。

摘　　要：目的评估德谷胰岛素联合达格列净对于老年2型糖尿病患者的降糖效果及其安全性。方法于石家庄市人民医院选取血糖控制不佳的老年2型糖尿病患者90例,随机分为对照组、甘精组和徳谷组,每组30例。对照组给予达格列净治疗,甘精组和徳谷组分别给予达格列净联合相应胰岛素治疗。每2周随访1次,共观察12周,随访时记录受试者的FPG和胰岛素使用剂量。于试验开始和结束时抽血检测患者血糖、胰岛素、HbA1c和血脂等指标。结果随访结束时,甘精组和徳谷组的FPG和HbA1c水平低于对照组(P<0.05),甘精组和德谷组的HbA1c水平比较,差异无统计学意义(P>0.05),但徳谷组FPG水平、胰岛素用量低于甘精组(P<0.05)。3组研究对象在治疗后的体重、FPG和HbA1c水平均低于各自的基线状态,差异有统计学意义(P<0.05)。随访过程中,徳谷组受试者发生低血糖的风险低于甘精组(P<0.05)。结论德谷胰岛素联合达格列净治疗老年2型糖尿病患者疗效显著,安全性较高,值得临床推广。Objective To evaluate the hypoglycemic effect and safety of insulin degludec combined with dapagliflozin in elderly patients with type 2 diabetes mellitus(T2DM).Methods A total of 90 elderly T2DM patients with a poor plasma glucose control treated in the Shijiazhuang People’s Hospital were randomly divided into the control group,insulin glarigine group(IGlar group)and insulin degludec group(IDeg group),with 30 cases in each group.Patients in the three groups were treated with dapagliflozin,dapagliflozin combined with insulin glarigine,and dapagliflozin combined with insulin degludec,respectively.They were followed up once every two weeks,for a total of 12 weeks.Fasting plasma glucose(FPG)and insulin dose were recorded during the follow-up.Blood samples were taken at the beginning and the end of the trial to measure indicators like plasma glucose,insulin,hemoglobin A1C(HbA1c)and lipids.Results At the end of the follow-up,FPG and HbA1c levels in the IGlar group and IDeg group were significantly lower than those in the control group(P<0.05).There was no significant difference in the HbA1c between IGlar group and IDeg group(P>0.05),but FPG and insulin dosage in the IGlar group were significantly lower than those in the IGlar group(P<0.05).After the treatment,the body weight,FPG and HbA1c levels of all the three groups were significantly lower than baseline(P<0.05).During the follow-up,the risk of hypoglycemia in the IDeg group was significantly lower than that in the IGlar group(P<0.05).Conclusion Insulin degludec combined with dapagliflozin has significant curative effect and high safety in the treatment of elderly T2DM patients,which is worthy of clinical promotion.

关 键 词：德谷胰岛素 甘精胰岛素 达格列净 老年 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]